Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

ICU blood test may predict deadly clots

NCT ID NCT06357403

Knowledge-focused Sponsor: Medical University of Vienna Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This observational study will follow 1300 critically ill adults in intensive care to see if a blood test called anti-factor Xa activity can predict dangerous blood clots (deep vein thrombosis or pulmonary embolism). Researchers will also track bleeding risks, quality of life, and survival. The goal is to better understand how to prevent clots in very sick patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,300 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2024

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients admitted to an surgical or medical intensive care unit who do not receive therapeutic anticoagulation

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age over 18 years at the time of intensive care unit admission * Admission to a participating intensive care unit within the last 24 hours * Expected discharge is later than 48 hours after enrolment Exclusion Criteria: * Therapeutic anticoagulation, defined as enoxaparin dose of at least 100 IE/kg when given twice daily or of at least 150 IE/kg when given once daily * Extracorporeal membrane oxygenation in place or planned within 48 hours of study enrolment * Planned regular administration of vitamin K antagonists, unfractionated heparin, low molecular weight heparin other than enoxaparin, thrombin inhibitors or factor X inhibitors within the observation period * Estimated life expectancy below 48 hours or comfort terminal care order in place * Previously diagnosed heparin-induced thrombocytopenia * Pre-operative admission for elective surgery * Previous enrolment in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Enoxaparin are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pulmonary embolism thrombotic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Enoxaparin Pulmonary embolism Thrombosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Anaesthesia, Intensive Care Medicine and Pain Medicine, Medical University of Vienna

    RECRUITING

    Vienna, 1090, Austria

  • Department of Internal Medicine, Medical University of Graz

    RECRUITING

    Graz, Styria, 8063, Austria

  • Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck

    RECRUITING

    Innsbruck, Tyrol, 6020, Austria

More trials for these conditions

Other studies related to the condition(s) this trial covers.